Maxygen to form joint venture with Astellas, shedding most of its R&D(0)
Maxygen, the Redwood City biotech company that hired Lazard last October to help it explore “strategic options” about the same time it laid off 30 percent of its staff, announced plans today for a deal with Astellas Pharma of Japan that will transfer most of its research and development operations and personnel to the a new joint venture funded by $10 million co-payments by both companies.
Maxygen will contribute substantially all of its Read the rest of this entry »
Subscribe via RSS all feeds